June 11th, 2026
In recent years, greater attention has been given to efforts that push back against the present broad acceptance of established data on human life expectancy, particularly for the oldest surviving cohorts. It has been suggested, and the evidence for this assertion is broadly supportive, that the published data for exceptional longevity is largely of poor quality, and much of what has been hyped over the years (such as Blue Zones or Jeanne Calment's alleged life span of 122 years) is simply not real.
What is observed in the data is a selection effect for error, fraud, and outright falsehood that grows stronger at advancing ages. We should be quite confident that a small number of humans can survive into their 110s, as individual cases have been well vetted, but we should be much less confident about the accuracy of demographics of survival much past age 90.
Does any of this really matter? From the perspective of building therapies to treat aging, I think probably not. It doesn't affect the need for better ways to measure biological age than exist at present, and it doesn't change the list of programs and targets that should be undertaken to produce potential rejuvenation therapies. People do get somewhat up in arms about the demographics of aging, but it seems a tempest in a teacup to me, somewhat irrelevant to the real issue of making progress in the treatment of aging as a medical condition. Other people may see it differently, of course.
